Global Venturing Review

The Big Ones It is the sort of line to awaken the curiosity in an annual report: “Cash payments to acquire equity investments amounted to £258m [$314m] (2018 – £309m), primarily relating to Lyell Immunopharma.” Thus, the accountants revealed UK-listed drugs maker GlaxoSmithKline (GSK) had invested a sizeable amount in US-based cancer treatment developer Lyell Immunopharma, … Continue reading "06 April 2020 – Lyell Immunopharma Gains $493m Investment from GlaxoSmithKline"